NCT02872415 (NOBOBO) is a NA clinical trial of Blood puncture site in Great Premature Newborn, sponsored by Assistance Publique Hopitaux De Marseille.

Who is sponsoring NCT02872415?

NCT02872415 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT02872415?

Interventions in NCT02872415: Blood puncture site.

What condition does NCT02872415 study?

NCT02872415 studies Great Premature Newborn.

Is NCT02872415 still recruiting?

NCT02872415 is currently completed. Last updated 26 May 2023.

Last reviewed 2023-05-26 · How we verify

NCT02872415: NOBOBO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Site on Pain in Preterm Neonates

Completed NA Last updated 26 May 2023

What this trial tests

NA trial testing Blood puncture site in Great Premature Newborn in 81 participants. Completed in 25 May 2023.

Timeline

10 May 2017

Primary endpoint
6 April 2018

25 May 2023

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	diagnostic
Enrollment	81
Start date	10 May 2017
Primary completion	6 April 2018
Estimated completion	25 May 2023
Sites	1 location across France

Drugs / interventions tested

Blood puncture site — full drug profile →

Conditions studied

Great Premature Newborn — all drugs for Great Premature Newborn →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

Adults 3 Hours to 72 Hours, any sex, with Great Premature Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Numerous experimental and clinical studies have shown that preterm neonates are particularly sensitive to stress. Preterm neonates routinely undergo painful invasive procedures. Each situation causing pain or discomfort can alter their development and cause short term cardiovascular consequences but also have long-term neurocognitive influences. Repetitive procedural pain can also lead to changes in the pain sensitivity threshold therefore. The most common painful procedures are lancing for blood glucose testing. In adults, infants and term newborns, forearm blood glucose testing has been demonstrated to be less painful than conventional sites (heel, fingers). But data is lacking in preterm neonates. The primary purpose of this study is to demonstrate a significant reduction in pain response during forearm blood lancing vs conventional sites (fingers, heel) in preterm neonates born up to 32 weeks gestation. This study is an interventional multicenter (3 centers), randomized, double bind trial with a cross over assignment. 60 premature neonates born between 23 to 32 weeks. Gestation with a postnatal age less than 72 hours that will undergo at least 3 blood glucose pricks will be included. The different sites will be randomly successively tested.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02872415 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 26 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02872415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing